Johnson & Johnson Announces Intention to Extend Longstanding VERMOX Donation Program through 2030 (2024)

News Report · Johnson & Johnson (press release, New Brunswick, New Jersey) · January 30, 2024

Johnson & Johnson (press release, 2024-01-30: J&J's own announcement extending its mebendazole (Vermox Chewable) donation through 2030, with up to 200 million doses a year and a stated 2.4 billion doses already provided in more than 60 countries since the programme launched in 2006. It is the company's account of the scale and dates of the donation programme.

The new five-year expanded commitment, announced on World Neglected Tropical Diseases (NTD) Day, will ensure that up to one billion doses of the medicine, or up to 200 million doses per year, are available to treat children and women of reproductive age in endemic countries.

Johnson & Johnson (press release, 2024-01-30: J&J's own announcement extending its mebendazole (Vermox Chewable) donation through 2030, with up to 200 million doses a year and a stated 2.4 billion doses already provided in more than 60 countries since the programme launched in 2006. It is the company's account of the scale and dates of the donation programme. Company self-report; no independent audit figures in the release. Figures as stated by the issuer: launched 2006; over 2.4 billion doses in more than 60 countries to date; commitment of up to 1 billion doses / up to 200 million per year through 2030; 31 countries stated to no longer require preventive therapy. Neutral disclosure of a corporate donation programme – no inference of intent. Page undated at field level; press release dated 30 January 2024 on its face. Study type: news.